Medifocus Inc.

Medifocus Inc.

December 10, 2010 11:36 ET

Medifocus Inc. Announces Convertible Debenture Offering

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 10, 2010) -


Medifocus Inc. ("Medifocus") (TSX VENTURE:MFS)(PINK SHEETS:MDFZF) announces, subject to regulatory approval, an offering of up to $600,000 principal amount of convertible debentures (the "Convertible Debentures"). The Convertible Debentures mature on the date that is 12 months after the date of issuance (the "Maturity Date") and bear interest at 15% per annum, payable upon the earliest to occur of the Maturity Date or conversion in full into common shares of the Company.

The principal amount of the Convertible Debentures is convertible into common shares of the Company, at any time from the date of issuance until the Maturity Date, at a price equal to $0.11 per common share. The Company may also at any time, without penalty, prepay in whole or in part the principal amount and accrued interest of the Convertible Debentures.

The proceeds of this offering will be primarily used to initiate a pivotal phase III clinical trial using the Company's Microfocus APA 1000 System for the treatment of breast cancer (including all related professional expenses) and for working capital.

Medifocus owns a patented microwave focusing technology platform (the Adaptive Phased Array ("APA") technology), which can precisely target and control microwave energy to cause heating in cancerous tumors anywhere in the body reliably and repeatedly. The ability to target tumors with a precision controlled dose of heat can be used to destroy tumors at higher temperatures, to treat tumors in combination with chemotherapy and/or radiation at moderate temperatures for increased effectiveness and reduced toxicity and to trigger the targeted release of therapeutic drugs and genes at tumor sites at lower temperatures. While the core technology has been licensed from the Massachusetts Institute of Technology, Medifocus has further refined the precision of the microwave focusing and control ability and developed a commercial system dedicated exclusively for the treatment of Breast Cancer. Please visit for more details.

The TSXV has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this news release.

Contact Information